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Abstract
Purpose Conditioning therapy with high-dose melphalan (HDM) is associated with a high risk of gut toxicity, fever and 
infections in haematopoietic stem cell transplant (HSCT) recipients. However, validated preclinical models that adequately 
reflect clinical features of melphalan-induced toxicity are not available. We therefore aimed to develop a novel preclinical 
model of melphalan-induced toxicity that reflected well-defined clinical dynamics, as well as to identify targetable mecha-
nisms that drive intestinal injury.
Methods Male Wistar rats were treated with 4–8 mg/kg melphalan intravenously. The primary endpoint was plasma citrul-
line. Secondary endpoints included survival, weight loss, diarrhea, food/water intake, histopathology, body temperature, 
microbiota composition (16S sequencing) and bacterial translocation.
Results Melphalan 5 mg/kg caused self-limiting intestinal injury, severe neutropenia and fever while impairing the micro-
bial metabolome, prompting expansion of enteric pathogens. Intestinal inflammation was characterized by infiltration of 
polymorphic nuclear cells in the acute phases of mucosal injury, driving derangement of intestinal architecture. Ileal atrophy 
prevented bile acid reabsorption, exacerbating colonic injury via microbiota-dependent mechanisms.
Conclusion We developed a novel translational model of melphalan-induced toxicity, which has excellent homology with the 
well-known clinical features of HDM transplantation. Application of this model will accelerate fundamental and translational 
study of melphalan-induced toxicity, with the clinical parallels of this model ensuring a greater likelihood of clinical success.
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Introduction
Melphalan is an alkylating chemotherapeutic agent which 
has been in use for over 60 years and remains the corner-
stone of successful multiple myeloma (MM) treatment, even 
in the era of novel agents [1, 2]. While high-dose melpha-
lan (HDM, 200 mg/m2) is associated with optimal efficacy 
and survival [3], it is associated with significant toxicity, 
which currently limits its use in less fit and elderly patients. 
HDM induces considerable oral and gut toxicity (mucositis), 
and febrile neutropenia is seen in approximately 80–85% of 
patients [4, 5].
Breakdown of the mucosal barrier has been identified as 
a key risk factor for bacteremia [6, 7], permitting transloca-
tion of enteric pathogens into systemic circulation. While 
largely based on clinical observation, these findings strongly 
implicate acute gastrointestinal injury in the etiology of 
bacteremia and suggest that promoting the integrity of the 
mucosal barrier may control infection risk while simulta-
neously reducing use of antimicrobial agents and limiting 
disruption of the microbiota (dysbiosis). In turn, this would 
minimize deleterious effects of antibiotics and dysbiosis, 
which are increasingly reported to decrease overall survival 
[8–11], worsen acute and chronic toxicities [12–15] and 
drive the emergence of antibiotic-resistant strains [16].
Unfortunately, there remain no effective prophylactic or 
therapeutic interventions for HDM-induced gut toxicity [17]. 
In fact, despite demonstrated efficacy in other oncological 
cohorts, palifermin fails to have any appreciable impact in 
patients receiving HDM [18]. Our current inability to opti-
mally prevent or manage HDM-induced gut toxicity largely 
reflects a limited understanding of its core pathobiology. 
Clinically, the dynamics of mucosal injury caused by HDM 
are well-described, particularly relating to the longitudinal 
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changes in plasma citrulline—a validated biomarker of small 
intestinal enterocyte mass [5, 19, 20]. However, the unique 
molecular mechanisms that dictate the clinical phenotype 
are challenging to dissect given the practical obstacles in 
conducting invasive investigations in this highly vulnerable 
patient cohort. This is further compounded by the complete 
lack of translationally robust preclinical models.
To date, several preclinical studies have used melphalan-
based models [21] to evaluate interventions/mechanisms 
including epidermal growth factors [22] and caspase-11 
[23]. However, these models are mostly outdated, do not 
report key toxicity outcome measures and lack synergy with 
the clinical dynamics of HDM transplantation. As such, 
there is a clear disconnect between the clinical understand-
ing of HDM-induced gut toxicity and our ability to identify 
targetable mechanisms in a preclinical setting, hindering 
efforts to develop interventions that successfully translate to 
the clinic [24]. The current study therefore aimed to develop 
and characterize a new preclinical model of HDM-induced 
gut toxicity and identify candidate pathways for therapeutic 
intervention.
STAR methods
This study is reported using the ARRIVE guidelines for the 
accurate and reproducible reporting of animal research and 
the STAR methods for structured, transparent and accessible 
reporting.
Experimental model details
Ethical statement and animal husbandry
All animal studies were conducted in accordance with the 
ethical guidelines approved by the Dutch Centrale Commis-
sie Dierproeven (CCD) and the Institutional Animal Care 
and Use Committee of the University Medical Center Gro-
ningen, University of Groningen (RUG), under the License 
Number 171325-01. All animals were individually housed in 
conventional, open cages at the Centrale Dienst Proefdieren 
(CDP; Central Animal Facility) at the University Medical 
Center Groningen. Rats were housed under 12 h light/dark 
cycles with ad libitum access to autoclaved AIN93G rodent 
chow and sterile water. Sawdust bedding was provided in all 
cases as well as a toilet roll for enrichment. All cages were 
randomly arranged across racks to prevent potential bias.
Study design
Animal experiments were performed as an initial dose find-
ing study (4–8 mg/kg melphalan, sourced from the Phar-
machemie Holding, B.V. The Netherlands), in which body 
weight, diarrhea, food/water intake and plasma citrulline 
were used to determine the optimal dose of melphalan in 
which moderate, self-limiting mucositis was achieved (based 
on citrulline dynamics). A dose validation study was then 
performed using the optimized dose of melphalan (5 mg/
kg) for which all endpoint analyses were performed (N = 24 
vehicle, N = 24 melphalan). In both cases, male Wistar rats 
weighing between 80 and 100 g were allowed to acclimatize 
for 10 days after arriving at the CDP. Rats were then ran-
domized to receive 4 (N = 6), 5 (N = 6 dose finding, N = 24 
dose validation), 6 (N = 6) or 8 mg/kg (N = 3) melphalan 
(10 mg/ml), or a volume equivalent dose of vehicle solution 
(0.9% NaCl, N = 3 dose finding, N = 24 dose validation). All 
intravenous injections were performed via the penile vein 
under anesthetic (3% isoflurane) on day 0. Minor adjust-
ments were made to random allocation to ensure experi-
mental groups exhibited comparable baseline body weight.
Melphalan treatment and tissue preparation
Rats received a single intravenous injection of melphalan 
(10 mg/ml, 4–8 mg/kg) or vehicle solution on day 0 of the 
experimental time course (Figure S1). Melphalan or vehicle 
control was administered via the penile vein at 10 am in 
designated procedure rooms within the CDP. For initial dose 
finding studies, all rats were sacrificed via isoflurane anes-
thesia, cardiac puncture and cervical dislocation at day 10 
(recovery). For dose validation studies (5 mg/kg), groups of 
rats were followed longitudinally until day 10 (N = 8/group). 
Subsets of rats were sacrificed on day 4 (N = 4/group) and 
day 7 (N = 4/group) for exploratory investigation.
At sacrifice, the liver, spleen, kidneys and cecum were 
weighed, and intestinal lengths recorded. All organs were 
drop-fixed in 10% neutral buffered formalin before being 
processed and embedded in paraffin. Cecal contents were 
snap frozen in liquid nitrogen. Intestinal resections were 
flushed with ice-cold, sterile 1 X phosphate buffered saline 
(PBS) and 1 cm sections were prepared for fixation in 10% 
neutral buffered saline, snap frozen in liquid nitrogen.
The primary outcome of the study was plasma citrulline, 
a validated biomarker of mucosal injury [19, 20, 25–27]. 
Secondary outcomes included survival, weight loss, diar-
rhea, white blood cell counts, body temperature, peripheral 
cytokines, blood cultures, intestinal barrier function, intes-
tinal morphology (determined histopathologically), micro-
biome composition, short chain fatty acid (SCFA) profiles 
and plasma bile acids.
Method detail
Clinical toxicity assessment
Systemic toxicity was assessed using clinical parameters 
of body weight, food intake and water intake, as well as 
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routine welfare indicators (reluctance to move, posture, coat 
condition). Rats were weighed daily, and water/food intake 
monitored by manual weighing of chow and water bottles. 
Gut toxicity was determined by diarrhea severity assessed 
using a validated, semi-quantitative scoring system (0–3) 
where 0 = no diarrhea, 1 = mild diarrhea with soft stools and 
perianal staining, 2 = moderate diarrhea with loose stools 
and perianal staining of fur, 3 = severe diarrhea with watery 
stools with or without mucous, and fur staining incorporat-
ing the hind legs. This assessment scale has been used in 
both rats [28] and mice [29] treated with chemotherapy.
Plasma citrulline
Plasma citrulline is an indicator of small intestinal entero-
cyte mass, and a validated biomarker of small intestinal tox-
icity [19, 20]. Repeated blood samples (75 μl) were collected 
from the tail vein into EDTA-treated hematocrit capillary 
tubes on day 0, 1, 2, 3, 4, 6, 8 and 10 (for dose finding stud-
ies) and days 0, 2, 4, 6, 7, 8 and 10 for dose validation stud-
ies (between 8:00 and 10:00 am). Citrulline was determined 
in 30 μl of plasma (isolated from whole blood via centrifu-
gation at 4000g for 10 min) using automated ion exchange 
column chromatography as previously  described10.
Differential blood analysis
Whole blood samples (200  μl) were collected into 
 MiniCollect®EDTA tubes from the tail vein of all rats at the 
time of treatment (day 0) and time of termination (Day 4, 7, 
10). Differential morphological analysis included  (109/L and 
% unless defined otherwise): white blood cell count (WBC), 
red blood cell count (RBC), hemoglobin (HGB, mmol/L), 
hematocrit (HCT, L/L), mean corpuscle volume (MCV, 
fL), platelet count (PLT,  109/L), nucleated red blood cell 
(NRBC) and WBC differentials (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils). Differential morpho-
logical analyses were performed using routine protocols in 
the diagnostics suite (Dept Hematology) at the University 
Medical Centre Groningen.
Body temperature
Core body temperature was used as an indicator of fever 
and was assessed daily using the Plexx B.V. DAS-7007R 
handheld reader and IPT programmable transponders. Tran-
sponders were inserted subcutaneously under mild 2% iso-
flurane anesthesia on day− 4 (Figure S1). Body temperature 
was assessed once daily between 8:00 and 10:00 am. Aver-
age values from day − 4 to − 1 were considered as baseline 
body temperature.
Intestinal barrier function
Intestinal barrier function was assessed using 4 kDa fluo-
rescein isothiocyanate (FITC)-dextran (Sigma-Aldrich) as 
previously described [30]. Briefly, FITC-dextran was pre-
pared at a concentration of 120 mg/ml in sterile 1 X PBS 
(pH 7.4) and kept on ice, protected from light until admin-
istration. FITC-dextran (500 mg/kg) was administered to 
rats via oral gavage 3 h prior to termination. Administra-
tion was staggered in 15 min intervals to account for the 
time taken to terminate each animal and collect biospeci-
mens. FITC-dextran concentrations were determined in 
plasma relative to a standard curve (0.0001–10 μg/ml) 
using the BioTek Synergy Mx Microplate Reader and 
Gen5 software.
Histology
Routine hematoxylin and eosin (H and E) staining was 
performed on jejunum, ileum and colon segments to evalu-
ate intestinal architecture. Briefly, drop-fixed tissue was 
processed and embedded into paraffin wax. 4 μm sections 
were cut on a rotary microtome and mounted onto glass 
 Superfrost® slides. H and E staining was performed as 
per routine protocols and slides were scanned using the 
Hamamatsu Photonics Digital Slide Scanner (NanoZoomer 
S60). Images were evaluated in a blinded fashion using 
the NDP.view2 software. Villus height and crypt depth 
were measured using annotation tools in NDP.view2.10 
well-oriented crypts/villi were measured per slide and an 
average calculated per animal.
Intestinal inflammation was determined by quantifi-
cation of infiltrating polymorphic nuclear cells (PMNC) 
in the jejunum and colon, which were assessed in four 
regions (500 × 500 μm). Individual counts were averaged 
over the four regions to generate a single mean value for 
each specimen.
Blood culture
At termination, whole blood was collected via cardiac 
puncture and 2 ml was immediately dispensed into BD 
 BACTEC™ PEDS  Plus™/F plastic blood culture bottles. 
Bottles were stored at room temperature before being 
transported to the Medical Microbiology laboratory at 
the University Medical Centre. Culture bottles were incu-
bated in the BD  BACTEC™ Automated Blood Culture 
System for 96 h. Positive cultures were identified using 
matrix-assisted laser desorption/ionization-time of flight 
(MALDI-TOF) mass spectrometry (MS).
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Microbiome analysis
Microbiota analysis was performed on repeated fecal sam-
ples collected on day 0, 4, 7 and 10 from N = 8 animals per 
group. Samples were collected aseptically and stored at 
− 20 °C. 16S rRNA Illumina sequencing was used to deter-
mine the composition of the fecal microbiota. All experi-
mental procedures (DNA extraction, PCR amplification, 
PCR product quantification and pooling, purification, library 
preparation and sequencing) were performed by Novogene. 
For full methodology, please see ‘Supplementary methods’.
Short chain fatty acid analysis
Short chain fatty acids (SCFAs) were analyzed in cecal 
contents collected at termination. Briefly, the cecum was 
removed and the apex cut using sterile scissors. The con-
tents were squeezed directly into a sterile 2 ml Eppendorf 
tube, snap frozen in liquid nitrogen and stored at − 80 °C. 
SCFAs were analyzed using gas chromatography adapted 
from Moreau et al. (2003) with minor adjustments [31]. Val-
ues were determined relative to a 7-point calibration curve 
(acetate: 0.0 and 8.0 mM; propionate: 0.0–4.0 mM; butyrate: 
0.0–4.0 mM). Cecal contents were thawed on ice and diluted 
1:9 with sterile, milliQ water and refrozen at − 80 °C. On 
the day of analysis, samples were thawed on ice and 500 µl 
was added to 500 μl of calibration sample, 100 μl internal 
standard solution (1 mg/ml 2-ethylbutyrate in Milli-Q), 20 μl 
20% (w/v) sulphosalicylic acid solution and two drops 37% 
HCl were added. The sample was centrifuged at 16,100g 
for 20 min at 4 °C, and supernatant was transferred to a 
glass tube containing a spatula tip of sodium chloride. 2 ml 
of diethylether was added and the sample was vortexed for 
10 min at room temperature and spun down at 3000g for 
10 min at 4 °C. From the clear upper layer, a 500 μl ali-
quot was taken and transferred to a glass GC-vial. 50 μl of 
MBTSTFA + 1% TBDMCS was added and left to derivatize 
overnight at room temperature. 3 μl derivatized sample was 
injected into the GC–MS (7890A GC system and 5975C 
inert XI EI/CI MSD with an EI inert 350 source). Analy-
sis was carried out in a split mode with an inlet split ratio 
of 20:1. Samples were analyzed in SIM acquisition mode; 
acetate at m/z 117, propionate at m/z 131, butyrate at m/z 145 
and 2-ethylbutyrate at m/z 175. Injector, source and quadru-
pole temperatures were 280 °C, 230 °C and 150 °C, respec-
tively. A Zebron capillary GC column of 30 m × 0.25 mm, 
0.25 μm film thickness was used (ZB-1, Phenomenex, Tor-
rance, USA). The GC oven was programmed as follows: 
40 °C held for 0 min, increased to 70 °C at 5 °C min-1, 
held at 70 °C for 3.5 min, increase to 160 °C at 20 °C min-
1, increased to 280 °C at 35 °C min-1 and finally held at 
280 °C for 3 min with a total run time of 20.43 min. The 
flow was set a 1.0 ml min-1 with helium as carrier gas. Data 
processing was carried out with MassHunter Workstation 
Software (MassHunter, Agilent Technologies).
Bile acids and ileal gene expression
Bile acid profiles were determined in plasma isolated from 
whole blood collected at termination (by cardiac puncture). 
Plasma bile acids were quantified using an Ultra High Per-
formance Liquid Chromatography system (SHIMADZU, 
Kyoto, Japan), coupled to a SCIEX QTRAP 4500 MD triple 
quadruple mass spectrometer (SCIEX, Framingham, MA, 
USA) (UHPLC-MS/MS) as previously described [32, 33]. 
Gene expression analysis was performed in on distal ileal 
segments, aligning with transporter expression, which were 
stored in RNAlater at − 20 °C. Total RNA was isolated using 
TRI-reagent (Sigma, St. Louis, MO, USA) and quantified 
by NanoDrop (NanoDrop Technologies, Wilmington, DE, 
USA). cDNA synthesis was performed from 1 µg of total 
RNA. Primers were designed with Primer-BLAST and opti-
mized for use with SYBR Green Master Mix (Roche Diag-
nostics, Mannheim, Germany) (maximum product size 150 
nucleotides). Real-time qPCR analysis was performed on 
a  StepOnePlus™ Real-Time PCR System (Applied Biosys-
tems, Thermo Fisher, Darmstadt, Germany). Gene expres-
sion levels were normalized to Ubc. Results were quantified 
using the comparative Ct method.
Quantification and statistical analyses
All data were analyzed using GraphPad Prism version 8.0 
with the exception of microbiota (16S rRNA) data. Continu-
ous data were analyzed for normality using the D’Agostino 
and Pearson test and Kolmogorov–Smirnov test. When 
normality was confirmed, a two-way analysis of variance 
(ANOVA) or mixed model (when data points were miss-
ing) was used to identify statistically significant differences. 
When normality was not confirmed, a Kruskal–Wallis with 
Dunn’s correction for multiple comparisons was used. 
Where possible, paired or repeated measures were prior-
itized and indicated using line graphs. In cases where this 
was not possible, biospecimens collected at termination were 
used and indicated by grouped data (column/bar graphs). In 
all cases, P < 0.05 was considered statistically significant.
Results
This study was performed as two distinct experiments: 
(1) dose finding study to identify the optimal dose of 
melphalan able to induce moderate, self-limiting gut 
toxicity, and (2) dose validation study to explore disease 
mechanisms. This study has been reported in accordance 
with the ARRIVE guidelines for transparent preclinical 
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reporting. Baseline characteristics of the dose validation 
study were compared between control and melphalan 
groups (Table S1). There were no statistically significant 
differences in baseline body weight, body temperature, 
plasma citrulline, food intake or water intake between 
vehicle control animals and melphalan-treated rats.
Intravenous melphalan induces a dose‑dependent 
phenotype characterized by weight loss, diarrhea 
and mucosal injury
All rats received a single dose of melphalan at the desig-
nated body weight-dependent dose (4–8 mg/kg dose find-
ing). Melphalan caused severe toxicity at doses of 6 mg/kg 
and 8 mg/kg with 100% mortality observed in rats treated 
with the highest dose (8 mg/kg; Fig. 1a). Melphalan caused 
Fig. 1  Dose finding study. To determine the optimal dose of melpha-
lan, rats were treated with 4, 5, 6, and 8 mg/kg intravenous melpha-
lan and clinical measures of gastrointestinal mucositis assessed for 
10 days. Doses of 6 and 8 mg/kg caused unaccepted morbidity and 
mortality (a/b). 5  mg/kg melphalan-induced moderate, self-limiting 
disease. Weight loss at day 4 was dose-dependent (c) and correlated 
with plasma citrulline (d–f). Hypocitrullinemia in first 2  days after 
melphalan was independent of dose and did not correlate with acute 
weight loss (g). Diarrhea severity was dose-dependent (h–l). Non-lin-
ear regression analyses with Pearson’s correlation analysis was per-
formed for all association plots
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dose-dependent weight loss (Fig. 1b), with maximum weight 
loss observed at day 4 at self-limiting doses (Fig. 1c). Mel-
phalan caused a rapid decrease in plasma citrulline, which 
was lowest at day 4 (15.25 ± 1.06  μM). Citrulline was 
strongly correlated with weight loss at day 4 (R2 = 0.9927, 
P < 0.0001), validating its applicability as a biomarker of gut 
toxicity (Fig. 1d–g). Hypocitrullinemia (< 10 μM) was evi-
dent at doses of 6 mg/kg and 8 mg/kg; however, these doses 
were also accompanied by unacceptable diarrhea severity 
and mortality (100% for 8 mg/kg, Fig. 1h–l). Melphalan 
administered at 5 mg/kg caused self-limiting gut toxicity, 
with transient grade 1 diarrhea peaking at day 7 (Fig. 1j).
Five mg/kg intravenous melphalan causes 
a biphasic, self‑limiting clinical phenotype 
accompanied by fever and severe neutropenia
Melphalan at 5 mg/kg caused significant weight loss com-
pared to vehicle control animals (− 6.4 ± 1.01% relative 
to baseline, P < 0.0001 Fig. 2a/b). Significant decreases 
in citrulline were evident on day 2 (84.1 ± 1.9  μM vs 
37.6 ± 1.3  μM, P < 0.0001), day 4 (81.5 ± 2.4  μM vs 
12.8 ± 1.24 μM, P < 0.0001) and day 7 (78.6 ± 2.7 μM vs 
59.2 ± 14.0 μM, P = 0.012), returning to baseline by day 10 
(Fig. 2c). In melphalan-treated animals, weight loss and cit-
rulline were moderately correlated (R2 = 0.433, P < 0.0001). 
Melphalan also caused a significant reduction in food con-
sumption, which was significant from day 1 to 7 (Fig. 2e); 
however, this was not accompanied by any change in water 
intake (Fig. 2f).
Fig. 2  Dose validation study with 5  mg/kg intravenous melphalan. 
Melphalan caused transient weight loss (a–b) and hypocitrullinemia 
(c), with a strong correlation between melphalan-induced weight loss 
and citrulline (d). Melphalan caused anorexia (e) but did not affect 
water intake (f). Body temperature spiked 6  days post-melphalan 
(g) coinciding with white blood cell nadir (h–i). Data represented as 
individual values (a, d), mean ± SEM (b–h, excluding d) or stacked 
means (i). Simple linear regression analysis (± 95% CI) with Pear-
son’s correlation was performed for all association plots
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To ensure clinical parallels, we also evaluated body tem-
perature and white blood cell (WBC) dynamics post-mel-
phalan treatment. Body temperature spiked at day 6 in mel-
phalan-treated animals (− 0.14 ± 0.10 °C vs + 0.70 ± 0.09 °C, 
P < 0.0001, Fig. 2g). Melphalan also induced severe leuco-
penia, with a significant decrease in total WBC count at day 
4 (6.1 ± 0.8 ×  109/L vs 1.0 ± 0.2 ×  109/L, P = 0.03, Fig. 2h), 
day 7 (4.8 ± 0.1 ×  109/L vs 0.7 ± 0.1 ×  109/L, P < 0.0001, 
Fig. 2h) and day 10 (5.2 ± 0.4 ×  109/L vs 3.0 ± 0.6 ×  109/L, 
P = 0.02, Fig. 2h). This was explained by significant ablation 
of neutrophils (P < 0.03), lymphocytes (P < 0.0001), mono-
cytes (P = 0.01) and basophils (P = 0.03; Fig. 2i).
Melphalan causes severe histopathological injury 
in the small and large intestine
Melphalan caused severe architectural injury in the small 
and large intestine, characterized by severe villus blunt-
ing/atrophy and crypt degeneration at day 4 (Fig.  3). 
Villus height was significantly decreased in melphalan-
treated animals compared to controls in the jejunum 
(481.1 ± 6.5 μm vs 204.3 ± 20.3 μm, P = 0.001, Fig. 3a) 
and ileum (284.3 ± 12.7 μm vs 143.8 ± 18.6 μm, P = 0.004, 
Fig. 3b). Crypt depth was significantly increased in the jeju-
num at day 4 (141.6 ± 3.2 μm vs 161.0 ± 1.7 μm, P = 0.03, 
Fig.  3c) and day 7 (127.2 ± 4.3  μm vs 170.9 ± 9.7  μm, 
P = 0.006, Fig. 3c). In contrast, crypt depth in the ileum 
was significantly decreased at day 4 (145.2 ± 1.1 μm vs 
126.3 ± 3.8 μm, P = 0.04, Fig. 3d) in melphalan-treated rats 
compared to controls, while an increase was observed at day 
7 (149.4 ± 5.6 μm vs 199.7 ± 4.1 μm, P = 0.006, Fig. 3d). 
No significant changes in crypt depth were observed for the 
colon (Fig. 3e).
To further validate citrulline as a surrogate marker of 
histopathological parameters of gut toxicity (gold-standard 
assessment), we evaluated the association between citrul-
line and villus/crypt height/depth. Strong correlations 
were observed between villus height and citrulline for both 
the jejunum and ileum (R2 = 0.68, R2 = 0.62, respectively, 
P < 0.0001, Fig. 3f). Significant, but less robust correla-
tions were observed for citrulline and crypt depth for the 
ileum and colon (R2 = 0.31, P = 0.001; R2 = 0.55, P < 0.0001, 
respectively, Fig. 3g).
In addition to villus blunting and changes in crypt depth, 
melphalan caused severe architectural derangement in the 
small and large intestine, characterized by villus fusion 
and crypt ablation (Fig. 3h), with evidence of gross colonic 
pathology seen at day 7 [Fig. 3i (i)]. Histological analysis of 
a macroscopically evident colonic perforation showed com-
plete destruction of the mucosa, submucosa and muscularis 
layer [Fig. 3i (ii)], with pseudomembrane development and 
visible inflammatory infiltrate [Fig. 3i (iii)]. Infiltration of 
polymorphic nuclear cells (PMNC) was also elevated in the 
jejunum of melphalan-treated rats (Fig. 4).
Melphalan‑induced microbiota disruption 
is characterized by pathogen expansion and SCFA 
deficits
16S rRNA-gene analysis was performed in fecal samples 
collected longitudinally (control and melphalan, N = 8 per 
group) on day 0, 4, 7 and 10. Melphalan-induced significant 
disruption of the fecal microbiota that failed to recover dur-
ing the 10-day experimental period (Fig. 5). Composition-
ally, there was a shift towards a Firmicute-dominated micro-
biota with expansion of pathogenic taxa largely belonging to 
the Proteobacteria phylum (Fig. 5a) which was not observed 
in control animals. This was accompanied by a decrease 
in the number of operational taxonomic units (OTUs), an 
indicator of microbial richness, which was significantly 
decreased 7  days post-melphalan compared to controls 
(P = 0.009, Fig. 5b). There were no significant changes in 
alpha diversity parameters, including Chao1, Simpson index 
and Shannon’s index in both control and melphalan-treated 
rats (data not shown). Principle component analyses showed 
no change in beta diversity of control animals (Fig. 5c). 
In contrast, significant changes were evident at all time 
points in melphalan-treated animals compared to baseline 
(P < 0.0001, Fig. 5d). These were also significant compared 
to controls at day 4 (P = 0.021) and day 7 (P = 0.015, data 
not shown).
While beta diversity and richness were most profoundly 
affected at day 7, expansion of pathogens was most sig-
nificant at day 4 post-melphalan (Fig. 5e), with significant 
increases in the abundance of Proteobacteria (P = 0.027), 
Betaproteobacteria (P = 0.021), Gammaproteobacteria 
(P = 0.015), Burkholderiales (P = 0.015), Enterobacteri-
ales (P = 0.021), Bacteroidaceae (P = 0.015), Enterobacte-
riaceae (P = 0.018), Bacteroides (P = 0.018), Escherichia-
shigella (P = 0.015), Clostridium sp. (P = 0.001), B. vulgatus 
(P = 0.006) and E. coli (P = 0.015). This was accompanied 
by a detectable decrease in Muribaculum (S24-7) in melpha-
lan-treated rats compared to controls (P = 0.017).
To determine the functional impact of microbial changes, 
short chain fatty acids (SCFAs) were quantified in cecal sam-
ples collected at termination at all time points. Significant 
decreases in acetate (9.25 ± 0.63 mM vs 3.75 ± 0.75 mM, 
P = 0.005, Fig.  6a), propionate (35.12 ± 4.02  mM vs 
14.75 ± 2.05  mM, P = 0.025, Fig.  6b) and butyrate 
(5.00 ± 0.58 mM vs 1.75 ± 0.47 mM, P = 0.015, Fig. 6c) 
were observed at day 4. Significant deficits in propionate and 
butyrate were also observed at day 10 (P = 0.027, P = 0.021, 
respectively).
Orally administered FITC-dextran was used to assess 
epithelial barrier permeability at all terminal time points. 
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Fig. 3  Five mg/kg intravenous melphalan causes severe anatomic 
derangement which correlates with plasma citrulline. Villus length (a, 
b) and crypt depth (c–e) were assessed at day 4, 7 and 10 and were 
correlated with matched plasma citrulline values (f–g). Panel h shows 
representative images of intestinal architecture. Panel i shows colonic 
perforation observed in one rat 7 days post-melphalan, with areas of 
frank ulceration (arrow) and total destruction of mucosa, submucosa 
and muscularis (i ii/iii). Data presented as mean ± SEM (a–e). All 
scale bars show 250um with the exception of panel i (ii) which shows 
1 mm. Simple linear regression analyses (± 95% CI) with Pearson’s 
correlation analysis was performed for all association plots
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While no significant changes were observed, the highest 
concentration of plasma FITC-dextran was observed on 
day 7 post-melphalan treatment (Figure S2). At this time 
point, we also identified one case of positive blood culture 
(E. coli). All other blood cultures were negative.
Melphalan‑induced ileal injury results in bile acid 
malabsorption and decreased plasma primary 
to secondary bile acid ratios
Plasma bile acids profiles were analyzed at termination 
on day 4, 7 and 10. Total plasma bile acid concentra-
tions and primary/secondary ratios were decreased in 
melphalan-treated animals on day 4 and 7 but this did not 
reach statistical significance (Fig. 7a, b). Upon analyz-
ing individual bile acid species, the primary conjugated 
bile acid, taurocholic acid (TCA), was decreased at all 
evaluated time points post-melphalan treatment (Fig. 7c, 
P = 0.006, P = 0.0004, P = 0.0001, respectively). The 
rodent-specific primary bile acid tauro-alpha-muricholic 
acid (T-α-MCA) was decreased at all time points (Fig. 7d, 
P = 0.01, P = 0.003, P = 0.009, respectively), while beta-
muricholic acid was unchanged (Fig. 7e). The secondary 
bile acid, deoxycholic acid (DCA), was unchanged by mel-
phalan treatment in its unconjugated form (supplementary 
data) but higher as taurine conjugate at day 4 (P = 0.001, 
Fig. 7f). All other bile acid concentrations are listed in 
Table S2.
Ileal gene expression analysis was performed at day 4 
for target genes involved in bile acid absorption and trans-
port (Fig. 7g). Ileal expression of t-Asbt, Fabp6 and Ostβ 
was significantly lower in melphalan treatment compared 
to controls, suggesting lower ileal absorption of bile acids 
(P = 0.03). In contrast, farnesoid X receptor (FXR) tar-
get genes Shp and Fgf15 were unchanged and increased 
(P = 0.03), respectively.
Discussion
The toxic properties of melphalan, mainly gut toxicity, fever 
and infections, currently prohibit expansion of its indication 
to older and less fit patients. Moreover, extensive antimi-
crobial drug use contributes to the growing global threat of 
antimicrobial resistance, disruption of gut microbiota, and 
increased costs.
Here, we highlight a critical advance in not only mod-
eling HDM-induced gut toxicity, but also the mechanisms 
that drive acute epithelial injury and secondary infectious 
complications. To our knowledge, this is the only preclinical 
model that recapitulates the clinically relevant interplay of 
events including mucosal injury, neutropenia, microbial dis-
ruption and fever caused by melphalan, and thus represents 
a translationally robust approach for the study of HSCT-
associated toxicities and evaluation of new interventions.
Intravenous melphalan (5 mg/kg) caused moderate, self-
limiting gut toxicity characterized by a clinically relevant 
phenotype. Critically, liquid biomarkers (citrulline), micro-
bial dynamics and toxic events mirror previously published 
clinical human datasets [5] and correlate with gold-standard 
histopathological criteria used in existing models of gut tox-
icity [29, 34, 35]. This reinforces the use of plasma citrul-
line as a minimally invasive liquid biomarker of gut toxicity, 
permitting repeated measures and reducing animal numbers. 
This highlights the applicability of this model for rapid inter-
ventional pre-screening with a greater likelihood of clinical 
success.
While many models have been successfully developed 
to understand chemotherapy-induced mucosal injury, many 
of these translate poorly to hematological malignancies in 
which mucositis is accompanied by severe neutropenia. 
While neutropenia has long been considered critical in driv-
ing infectious complications of HSCT, an increasing body of 
evidence suggests that neutropenia is not solely responsible 
Fig. 4  Melphalan-induced gastrointestinal injury is characterized 
by infiltration of polymorphic nuclear cells (PMNC) in the jejunum. 
(a) Representative images of the jejunum of melphalan-treated rats 
showing tissue destruction and inflammatory infiltrate. (b) Quantifi-
cation of PMNC infiltrate in the jejunum and colon. Data presented 
as mean ± SEM
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for infectious events often seen in HSCT recipients [7, 36, 
37]. Importantly, antimicrobial agents and hematopoietic 
growth factors have both failed to significantly reduce the 
incidence of infection/fever, with disruption of the host 
microbiota and breakdown of the mucosal barrier now 
considered critical factors in the initiation of blood stream 
infection. While no profound changes were identified in 
diversity and richness indices, melphalan treatment resulted 
in functional deficits in the microbial metabolome, indi-
cated by short chain fatty acid (SCFA) loss, resulting in a 
Fig. 5  Melphalan-induced dysbiosis is characterized by expansion 
of enteric pathogens. Panel a showed relative abundance for indi-
vidual animals assessed longitudinally over experimental time course. 
Data are shown at taxonomic level of order. OTUs were significantly 
decreased at day 7 post-melphalan (b), with principle component 
analyses demonstrating significant shifts in the microbiota post-mel-
phalan that were unable to resolve (c–d). Panel e shows significantly 
altered taxa (mean ± SEM) at day 4 and median difference between 
groups (median ± 95% CI)
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Fig. 6  Cecal short chain fatty acid (SCFA) profiles change following intravenous melphalan. Acetate (a), propionate (b) and butyrate (c) were all 
decreased at day 4 following melphalan. Data represented as mean ± SEM
Fig. 7  Bile acid malabsorption 
is seen in melphalan-treated 
rats. Bile acids were assessed 
in plasma isolated from whole 
blood collected at termination. 
No significant decreases were 
seen in total bile acid pool (a) or 
the ratio of primary to second-
ary bile acids (b). Significant 
decreases were identified for 
taurocholic acid (c) and tauro-
alpha-muricholic acid (d) but 
not for tauro-beta-muricholic 
acid (e). Taurodeoxycholic acid 
was increased in plasma on day 
4 (f). Ileal gene expression was 
performed for downstream bile 
acid targets at day 4 (g). Data 
shown as mean ± SEM
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pathogen-dominated microbiota. SCFAs serve to not only 
support mucosal homeostasis, but are critical in the acidi-
fication of the luminal environment; an important defense 
against the expansion of pathogens, particularly Enterobac-
teriaceae [38, 39]. As such, it is likely that loss of lumi-
nal SCFAs promotes self-perpetuating mucosal injury and 
microbial disruption that contribute to acute gut toxicity and 
infection risk (Fig S3).
Our model is the first to demonstrate significant expan-
sion of pathogenic microbes following melphalan treat-
ment, yet in the absence of antibiotics, coinciding with peak 
mucosal injury and inflammation and preceding fever and 
an isolated case of blood stream infection. Importantly, we 
showed significant fecal expansion of E. coli, which was 
identified by MALDI-TOF analysis of a positive blood cul-
ture. These results are consistent with reports from 2003 in 
which mucosal inflammation preceded bacteremia and fever 
[40] and align with findings demonstrating enteric domina-
tion by Enterobacteriaceae drastically increases the risk of 
bacteremia in allogeneic HSCT recipients [41, 42]. These 
data suggest translocation of endogenous microbes across 
a damaged mucosal barrier is a key driver of blood stream 
infection. Efforts to maintain the mucosal barrier and host 
microbiota are therefore warranted and may aid in reduc-
ing the over-reliance on antimicrobials. This is particularly 
relevant in the broader setting of HSCT, in which antibi-
otic-induced disruption of the microbiota has been shown to 
exacerbate graft-versus-host disease (GvHD) and increase 
mortality [12, 43].
The impact of antibiotics on the toxicity outcomes of 
HSCT has been the subject of intense investigation. In fact, 
the large majority of studies attribute microbial changes 
observed in HSCT to prophylactic and empirical antibiotic 
use (key studies summarized by Zama 2020 [44]). Here, 
we demonstrate that changes in the microbiota occur in the 
absence of antibiotics supporting either direct bactericidal 
properties of melphalan or mucosal-dependent mecha-
nisms of dysbiosis. However, we were surprised that alpha 
diversity indices did not capture the changes in microbial 
composition, with no changes in alpha diversity seen in our 
model. This is in contrast to clinical observations [45] where 
profound diversity changes were observed. The lack of 
change we detected in alpha diversity may simply reflect the 
underpowered nature of alpha diversity indices which may 
have underestimated the magnitude of effect. This could be 
explored by applying error models adjusted for uncertainty; 
however, this is beyond the scope of the current paper. Alter-
natively, our findings may simply suggest that antibiotics 
are required for a detectable change in alpha diversity, with 
HDM inducing compositional changes only. Nonetheless, 
we were encouraged to see microbial changes that were 
consistent with findings in patients undergoing HDM which 
were associated with diarrhea and culture-negative fever, 
reiterating the use of our model to further explore the rela-
tionship between the microbiome and treatment outcomes 
in HSCT recipients [45].
Consistent with the findings of Tsuji et al. (2003) and 
Taur et al. (2012), we observed a biphasic phenotype, with 
peak morbidity observed at day 4 and a secondary episode at 
day 6–7. Acute morbidity reflects direct cytotoxic injury to 
the intestinal mucosa, consistent with the findings reported 
in other longstanding models of gut toxicity [35]. However, 
histopathological analysis and plasma citrulline data indicate 
that the mucosa of the small intestine is recovering by day 
6–7. In contrast, colonic histopathological analysis identi-
fied residual injury at day 6–7, coinciding with peak intes-
tinal permeability (FITC-dextran) suggesting a recovering, 
yet immature and functionally deficient mucosa that does 
not exert the same degree of pre-melphalan barrier control 
[46]. As such, following the expansion of enteric patho-
gens, a leaky colonic barrier then permits translocation and 
prompts subsequent fever. This proposed interaction aligns 
with higher microbial load in the distal gastrointestinal tract, 
and higher abundance of innate immune receptors (such as 
Toll-like receptor 4) which are critical in the regulation of 
the intestinal barrier after chemotherapy [29, 47].
In addition to the fundamental insight we provide, our 
data also identify new therapeutic strategies that will miti-
gate acute gut toxicity with the goal of preventing infection 
and prompting appropriate antibiotic stewardship. Of par-
ticular interest were changes in bile acid metabolism, with 
our findings supporting use of bile acid sequestrants con-
sistent with their use in other gastrointestinal diseases [48].
Bile acid malabsorption (BAM) has been widely impli-
cated in the development of diarrhea, including diarrhea 
caused by the tyrosine kinase inhibitor neratinib [49] and in 
patients with GI-GvHD [50], increasing colonic secretion 
of water and electrolytes and the induction of propagated 
contractions [51]. We identified changes in plasma bile acids 
and ileal gene expression following melphalan, indicative of 
BAM. BAM increases the pool of luminal bile acids, with 
our data supporting microbiota-dependent production of sec-
ondary bile acids [52]. Importantly, we observed a relative 
increase of fecal bacteria from the Firmicutes phylum upon 
melphalan treatment. It is known that Firmicutes, especially 
certain Clostridia species, are able to 7-alpha-hydroxylate 
bile acids thus leading to an increased secondary pool as 
observed in our study [53, 54]. Secondary bile acids are 
mucotoxic and pro-inflammatory [55], and as such, their 
production may serve to amplify mucosal injury. The clini-
cal relevance of this finding is particularly compelling with 
BAM reported in severe cases of GvHD-related diarrhea 
and even bowel perforation [50, 56]. Bile acid sequestrants 
(colesevelam) may offer benefits in both the prevention of 
acute diarrhea (caused by motility/secretory mechanisms) as 
well as the prevention of colonic permeability responsible 
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for bacterial translocation. Coleveselam has already been 
deemed safe in oncology cohorts and has demonstrated clini-
cal efficacy in treatment neratinib-induced diarrhea [49, 57].
In summary, we have developed the first translational 
model of HDM-induced gut toxicity that reflects the clini-
cal phenotype of HSCT-associated toxicities. Our results 
reinforce the multi-factorial nature of gut toxicity and its 
symptomology, with direct cytotoxic injury an impor-
tant initiating factor in establishing various cascades of 
injury. This involves neutrophil recruitment, inflamma-
tion, microbial changes and bile acid disruption, each of 
which are likely to contribute to bacterial translocation and 
subsequent blood stream infection. Critically, we suggest 
that this sequence of events only stops when stem cells 
repopulate the intestinal lining, renewing niches to sup-
port the host’s commensal microbiota. Replenished SCFA 
production and normalized enterohepatic circulation then 
aid in re-establishing a functional barrier. These mechanis-
tic insights highlight that systemic reactions such as fever 
are a form of collateral damage resulting from breakdown 
of the intestinal mucosal/luminal environments. Efforts to 
intervene early in these sequelae are therefore of great 
clinical significance.
Supplementary Information The online version contains supplemen-
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